Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy

Brain : a Journal of Neurology
C H LyooM S Lee

Abstract

To study the effect of disease duration on the clinical, neuropsychological and [(18)F]-deoxyglucose (FDG) PET findings in patients with mixed type multiple system atrophy (MSA), this study included 16 controls and 37 mixed-type MSA patients with a shorter than a 3-year history of cerebellar or parkinsonian symptoms. We classified the patients into three groups according to the duration of parkinsonian or cerebellar symptoms (Group I = <or=1 year; II = 13-24 months; III = 25-36 months). We performed UPDRS, international cooperative ataxia rating scale (ICARS), and a neuropsychological test battery. We compared the FDG PET findings of each group of patients with controls. Group I patients frequently had memory and frontal executive dysfunction. They showed hypometabolism in the frontal cortex, anterior cerebellar hemisphere and vermis. They had parkinsonian motor deficits, but no basal ganglia hypometabolism. Group II and III patients frequently had multiple domain cognitive impairments, and showed hypometabolism in the frontal and parieto-temporal cortices. Hypometabolism of the bilateral caudate and the left posterolateral putamen was observed in Group II, and whole striatum in Group III. In summary, the cortical hypometabolis...Continue Reading

Citations

Jan 29, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Chrissa SiokaAthanassios P Kyritsis
May 28, 2009·Journal of Neurology·Gregor K Wenning, Nadia Stefanova
May 27, 2009·Journal of Neurology·Tae Sung LimSeok Woo Yong
Nov 26, 2008·Brain : a Journal of Neurology·Gilbert BensimonUNKNOWN NNIPPS Study Group
Jun 3, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C C ChangW L Liu
Apr 12, 2012·Neurology·K L PostonD Eidelberg
Aug 5, 2009·Biological & Pharmaceutical Bulletin·Wei ZhangFeng Zhang
Dec 11, 2013·Clinical Nuclear Medicine·Ümit Özgür AkdemirLütfiye Özlem Kapucu
Sep 20, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Hae Won KimChong Sik Lee
Aug 4, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M J LeeE-J Kim
Dec 17, 2015·Journal of the Neurological Sciences·Bei CaoHui-Fang Shang
Apr 7, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Teresa PellecchiaSabina Pappatà
Apr 23, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Iva StankovicUNKNOWN Movement Disorders Society MSA (MODIMSA) Study Group
May 20, 2015·Brain : a Journal of Neurology·Matthew D CykowskiJoseph E Parisi
Mar 27, 2013·Parkinsonism & Related Disorders·Han-Joon KimJee-Young Lee
Nov 11, 2014·The Cerebellum·Leonardo BaldarçaraChristophe Habas
Jul 30, 2016·European Journal of Nuclear Medicine and Molecular Imaging·Flavia Niccolini, Marios Politis
Oct 26, 2016·Journal of Neural Transmission·Eleonora FiorenzatoUNKNOWN Movement Disorders Society MSA (MODIMSA) Neuropsychology and Imaging Study Groups
Jul 16, 2016·The Clinical Neuropsychologist·Erin E RobertsonJoan A O'Keefe
Jul 4, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Eleonora FiorenzatoRoberta Biundo
Oct 7, 2017·Journal of Alzheimer's Disease : JAD·Kurt A Jellinger
Oct 13, 2017·Expert Review of Neurotherapeutics·Kurt A Jellinger
Sep 26, 2019·The Journal of International Medical Research·Jing GuoYong Luo
Feb 8, 2020·Annals of Clinical and Translational Neurology·Sabine EschlböckGregor K Wenning
Oct 23, 2018·Disability and Rehabilitation·Athanasia AlexoudiStylianos Gatzonis
Feb 12, 2019·Restorative Neurology and Neuroscience·LingYu ZhangHuiFang Shang
May 6, 2020·Journal of Neural Transmission·Kurt A Jellinger
Sep 29, 2019·Journal of Neurology·Francesca CasoFederica Agosta
Nov 11, 2019·Journal of Parkinson's Disease·Satoko SakakibaraMasahisa Katsuno
Dec 18, 2020·Frontiers in Aging Neuroscience·Junyu LinHuifang Shang
Dec 18, 2020·Frontiers in Neurology·Luisa SambatiPietro Cortelli
Oct 18, 2019·Parkinsonism & Related Disorders·Stephan GrimaldiAlexandre Eusebio
Apr 20, 2021·Frontiers in Neurology·Cong ShenJian Wang
Feb 11, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Minyoung OhChong Sik Lee
Sep 16, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Philipp T MeyerSabine Hellwig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.